Predictive factors for persistent thrombocytopenia after peptide receptor radioligand therapy in enteropancreatic neuroendocrine tumors

Predictive factors for persistent thrombocytopenia after peptide receptor radioligand therapy in enteropancreatic neuroendocrine tumors

IntroductionPeptide receptor radionuclide therapy (PRRT) is an effective and well-tolerated treatment for advanced neuroendocrine tumors (NETs). However, persistent thrombocytopenia (PT) has been reported and may compromise further therapies and outcomes. This study aimed to identify predictive fact...

Full description

Saved in:
Bibliographic Details
Main Authors: Romain Ferrara, Christophe Zemmour, Thibaut Reichert, Daniel Ouk, Patricia Niccoli, Jemima Maniry-Quellier, Isabelle Brenot-Rossi, Nathalie Charrier, Sandrine Oziel-Taieb
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Endocrinology
Subjects:
[177Lu]Lu-DOTATATE
neuroendocrine tumors
thrombocytopenia
bone metastases
spleen
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1568243/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2025.1568243/full

Similar Items